BTIG Remains a Buy on Alcon (ALC)

In a report released yesterday, Ryan Zimmerman from BTIG maintained a Buy rating on Alcon (ALCResearch Report), with a price target of $85.00. The company’s shares closed yesterday at $75.47.

According to TipRanks, Zimmerman is a 5-star analyst with an average return of 9.2% and a 46.89% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Vericel, Mediwound, and Penumbra.

Currently, the analyst consensus on Alcon is a Moderate Buy with an average price target of $84.22, which is an 11.59% upside from current levels. In a report released yesterday, Needham also reiterated a Buy rating on the stock with a $87.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

ALC market cap is currently $38.23B and has a P/E ratio of 81.06.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Alcon Inc. is a medical company which is specialized in eye care products. The company develops, manufactures, distributes, and sells technologies and devices for cataract, retinal, refractive surgery, as well as contact lenses and lens care products.

Read More on ALC:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed